The benefit of standard treatment of malignant glioma in older patients is
debated. In order to assess the effect of a combination of surgery, radioth
erapy and chemotherapy on survival of elderly patients with high grade glio
mas, 30 consecutive patients older than 70 years with malignant supratentor
ial gliomas were studied between 9/93 and 9/96. Median age was 73 years (70
-79). The mean Karnofsky performance status (KPS) was 66 (30-100). Patients
underwent maximum possible surgery, followed by a course of radiotherapy (
45 Gy/25 fractions/5 weeks) with 3 or 4 orthogonal beams and a 2 cm margin
around the tumor bed. The administration of chemotherapy was left at the di
scretion of the responsible physician and 12 patients received reduced dose
nitrosourea-based chemotherapy. The overall median survival was 36 weeks.
The median time to progression was 26 weeks. Three months after surgery, 26
patients were alive, 5 were in complete response, 2 in partial response an
d 10 were stabilized. Pre-radiotherapy KPS was the only significant prognos
tic factor with a median survival of 40 weeks in patients with KPS greater
than or equal to 70 and 25 weeks when KPS was > 70 (logrank test, p = 0.05)
. In responding and stable patients (57% of the group) the median KPS was 6
8 and 66 at 1 and 3 months after the completion of radiotherapy. There was
no case of radiotherapy-induced dementia with this regimen. Four out of 12
patients who received chemotherapy, experienced WHO grade 3/4 hematotoxicit
y.
This study suggest that some patients older than 70 years with KPS greater
than or equal to 70 may benefit from the treatment of malignant gliomas wit
h surgery followed by reduced dose of limited field radiotherapy. Further s
tudies are needed to define the most appropriate dose of radiotherapy and t
o evaluate further the risk/benefit ratio of a reduced dose chemotherapy in
this population.